Shalby Ltd
SHALBYShalby Ltd's earnings have outrun its stock. EPS grew +496.6% in a year against a −21.6% price move.
The sharpest disagreement: profits are rising, but only 13% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a downtrend (32 weeks in) while the P/E sits at the 72nd percentile of its own 9-year range. Underneath, the last four quarters read improving, and 13% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Shalby Ltd trades at ₹161, in a downtrend and 32 weeks into that stage. That is −8.7% against its own 200-day average. It sits at 22% of a 52-week range of ₹131 to ₹266. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is in a downtrend — week 32 of stage 4, confirmed. At ₹161 it trades −8.7% versus its 200-day average and sits at 22% of its 52-week range (₹131–₹266).
Against the market, two honest reads. Cumulative: over the last 8.6 years the stock moved −33% while the NIFTY 500 moved +151% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Shalby Ltd trades at 46.6× P/E, at the pricey end of its own range (72nd percentile). Its long-run median P/E is 37.1×, measured across 8.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 46.6× is at the pricey end of its own range (72nd percentile), against a long-run median of 37.1× measured over 8.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +496.6% against a −21.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −3.6%/yr price move, ~−2.5%/yr came from earnings growth and ~−1.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Shalby Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −100.0% at the trough to +250.0%, a 2-quarter improving streak (single-quarter readings), ROCE slipping at 6.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +5.0% | +12.3% | +21.5% | +14.7% |
| Profit | +1,650.0% | −19.9% | −3.6% | −0.3% |
| EPS | +496.6% | −18.0% | −2.5% | −2.2% |
| Share price | −21.6% | −6.3% | −3.6% | — |
4-Factor Sector Score
30.7/100 — rank 18 of 19 in Hospitals · 69% evidence confidence
Shalby Ltd scores 30.7 out of 100 against the 19 companies it is compared with in Hospitals, ranking 18. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 15.6 + 2.5 + 9.1 + 3.5 = 30.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Shalby Ltd reported ₹287 Cr of revenue in the Mar 26 quarter, +8.3% year on year. Over 10 years it has compounded at 14.7% a year. The last full year, FY26, came in at ₹1,141 Cr. The last four reported quarters add to ₹1,140 Cr.
FY26 revenue came in at ₹1,141 Cr (+5.0% on the year), capping 10 years at 14.7% compound. The latest quarter (Mar 26) printed ₹287 Cr, +8.3% year on year.
Pace check: the last four quarters averaged +4.8% growth against the decade's 14.7% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +4.8% over the last 4 quarters against +10.5%/yr over the last 8 — rolling over; TTM profit +1,600.0% vs −36.4%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Shalby Ltd's operating margin is 10.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0% to 25.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 10.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0%–25.0%.
Why the margin moved: operating margin went +2.3 pp year on year while gross margin went −1.4 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Shalby Ltd earned ₹18.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹35.0 Cr. The 10-year compound rate is −0.3%. That is 6.3% of the quarter's revenue. The same quarter a year earlier lost ₹12.0 Cr. 2 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹18.0 Cr, null year on year. On the full year, FY26 printed ₹35.0 Cr (+1,650.0%), and the 10-year compound rate is −0.3%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 13% of Shalby Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹0.0 Cr of operating cash against ₹35.0 Cr of profit. After ₹157 Cr of capital spending, ₹−157 Cr was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY26: operating cash of ₹0.0 Cr against reported profit of ₹35.0 Cr, leaving free cash of ₹−157 Cr after ₹157 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 13% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 13%: the cash cycle stretched 954 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 954 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Shalby Ltd's cash conversion cycle runs 671 days in FY26, up from −283 days in FY21. Capital spending ran ₹556 Cr over the last 3 years. At FY26 sales of ₹1,141 Cr each day of that cycle holds about ₹3.1 Cr, so roughly ₹2,098 Cr sits inside the business at any moment.
FY26: debtors at 73 days, inventory at 908 days — roughly 29.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 671 days, looser than FY21's −283.
The full loop: cash goes out to suppliers and production on day 0; stock waits 908 days to sell; customers pay about 73 days after that; and suppliers themselves are paid at 310 days — netting out to the 671-day cycle.
In money terms: at FY26 sales of ₹1,141 Cr, each day of the cycle holds about ₹3.1 Cr — so the 671-day loop keeps roughly ₹2,098 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹556 Cr over the last 3 fiscal years against ₹188 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Shalby Ltd earns a ROCE of 6% in FY26. That is up from a trough of 6% in FY25. Return on invested capital clears the cost of that capital by −9.2 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 3.1% net margin on 0.62× asset turns.
FY26 ROCE is 6%, recovered from a FY25 trough of 6% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 3.1% net margin × 0.62× asset turns × 1.83× balance-sheet leverage ≈ 3.5% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 2.8% − 12.0% = a −9.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Shalby Ltd carries total debt of ₹595 Cr against shareholder equity of ₹1,006 Cr as of Mar 26, a debt-to-equity of 0.59. On the annual view that ratio went from 0.20 in FY22 to 0.59 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹595 Cr against shareholder equity of ₹1,006 Cr — a debt-to-equity of 0.59. On the annual view, debt-to-equity went from 0.20 (FY22) to 0.59 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Shalby Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.2 points over the same window, to 0.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.9 points over 8 quarters to 4.5%; Domestic institutions: +0.2 points over 8 quarters to 0.3%; Promoters: +0.1 points over 8 quarters to 74.3%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Shalby Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1KMC Speciality Hospitals (India) Ltd524520 | 82.1/100Sector-leading setup78% evidence | LEADER | 30.8/35 Revenue 32.5% · PAT 100% · OPM change 6 pp 83% evidence | 20.6/25 ROCE 26% · OPM 31% 76% evidence | 11.2/20 P/E 44.5× · PEG — 50% evidence | 19.5/20 RS sector 34% · RS bench 44.3% · 1Y 97.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 20.6 + 11.2 + 19.5 = 82.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Artemis Medicare Services LtdARTEMISMED | 67.9/100Favorable setup96% evidence | LEADER | 24.4/35 Revenue 15.5% · PAT 24.1% · OPM change 3 pp 88% evidence | 12.0/25 ROCE 14.6% · OPM 18% 100% evidence | 14.4/20 P/E 44.6× · PEG 1.09 100% evidence | 17.1/20 RS sector 8.2% · RS bench 17.1% · 1Y 24.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 12 + 14.4 + 17.1 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Sakar Healthcare LtdSAKAR | 67.6/100Favorable setup87% evidence | LEADER | 32.2/35 Revenue 43.9% · PAT 71.4% · OPM change 5 pp 95% evidence | 11.0/25 ROCE 12.7% · OPM 29% 95% evidence | 6.9/20 P/E 54.6× · PEG — 50% evidence | 17.5/20 RS sector 57% · RS bench 68.5% · 1Y 144.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.2 + 11 + 6.9 + 17.5 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Apollo Hospitals Enterprise LtdAPOLLOHOSP | 67.1/100Favorable setup78% evidence | LEADER | 23.6/35 Revenue 15.8% · PAT 33% · OPM change 1 pp 83% evidence | 15.4/25 ROCE 17.9% · OPM 15% 76% evidence | 12.6/20 P/E 65.8× · PEG — 50% evidence | 15.5/20 RS sector 5.2% · RS bench 13.7% · 1Y 19.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 15.4 + 12.6 + 15.5 = 67.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Rainbow Childrens Medicare LtdRAINBOW | 58.0/100Mixed-positive evidence100% evidence | BREAKING OUT | 18.0/35 Revenue 18.3% · PAT 12.4% · OPM change 0 pp 100% evidence | 17.1/25 ROCE 17.4% · OPM 29% 100% evidence | 7.3/20 P/E 54.1× · PEG 2.97 100% evidence | 15.6/20 RS sector 4% · RS bench 12.4% · 1Y -2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 17.1 + 7.3 + 15.6 = 58 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Max Healthcare Institute LtdMAXHEALTH | 57.8/100Mixed-positive evidence90% evidence | TURNING | 25.1/35 Revenue 19.1% · PAT 34% · OPM change 1 pp 88% evidence | 15.8/25 ROCE 14.7% · OPM 28% 100% evidence | 10.8/20 P/E 72.1× · PEG 1.73 100% evidence | 6.1/20 RS sector -7.9% · RS bench 0.1% · 1Y -14.2%2 of 10 weeks ahead 70% evidence |
| Exact sum: 25.1 + 15.8 + 10.8 + 6.1 = 57.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.9% and the one-year return is -14.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Kovai Medical Center & Hospital LtdKOVAI | 54.6/100Mixed-positive evidence96% evidence | FADING | 17.8/35 Revenue 15.8% · PAT 16.2% · OPM change -1 pp 88% evidence | 21.3/25 ROCE 22.6% · OPM 27% 100% evidence | 10.4/20 P/E 26.3× · PEG 1.51 100% evidence | 5.1/20 RS sector -7.4% · RS bench 0.2% · 1Y -3.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 21.3 + 10.4 + 5.1 = 54.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Dr Agarwals Eye Hospital LtdDRAGARWQ | 54.3/100Mixed-positive evidence90% evidence | ASLEEP | 19.6/35 Revenue 18.6% · PAT 27.8% · OPM change -4 pp 88% evidence | 16.8/25 ROCE 17.4% · OPM 28% 100% evidence | 10.6/20 P/E 34.6× · PEG 1.72 100% evidence | 7.3/20 RS sector -4% · RS bench -1% · 1Y 13.4%4 of 7 weeks ahead 70% evidence |
| Exact sum: 19.6 + 16.8 + 10.6 + 7.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Global Health LtdMEDANTA | 54.1/100Mixed-positive evidence100% evidence | LEADER | 12.3/35 Revenue 21.3% · PAT 3.4% · OPM change -2 pp 100% evidence | 13.9/25 ROCE 17.1% · OPM 22% 100% evidence | 11.3/20 P/E 66× · PEG 1.11 100% evidence | 16.6/20 RS sector 4.5% · RS bench 13% · 1Y 6.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 13.9 + 11.3 + 16.6 = 54.1 · Decision use: Price leads the evidence: RS versus the benchmark is 13%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Indraprastha Medical Corporation LtdINDRAMEDCO | 52.2/100Mixed-positive evidence90% evidence | ASLEEP | 12.4/35 Revenue 9.3% · PAT 13.7% · OPM change -1 pp 88% evidence | 18.6/25 ROCE 35.8% · OPM 17% 100% evidence | 17.2/20 P/E 18.3× · PEG 0.92 100% evidence | 4.0/20 RS sector -8.4% · RS bench -17.3% · 1Y -20.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 18.6 + 17.2 + 4 = 52.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11Fortis Healthcare LtdFORTIS | 50.2/100Mixed-positive evidence78% evidence | FADING | 23.6/35 Revenue 17.3% · PAT 31.5% · OPM change 1 pp 83% evidence | 12.8/25 ROCE 13.4% · OPM 23% 76% evidence | 9.0/20 P/E 67.5× · PEG — 50% evidence | 4.8/20 RS sector -7.3% · RS bench 0.2% · 1Y 11.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 12.8 + 9 + 4.8 = 50.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.3% and the one-year return is 11.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Yatharth Hospital & Trauma Care Services LtdYATHARTH | 48.2/100Mixed-negative evidence78% evidence | FADING | 19.5/35 Revenue 36.1% · PAT 31.5% · OPM change -2 pp 83% evidence | 11.7/25 ROCE 12.4% · OPM 23% 76% evidence | 8.8/20 P/E 45× · PEG — 50% evidence | 8.2/20 RS sector 0.2% · RS bench 8.1% · 1Y 30.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 11.7 + 8.8 + 8.2 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13GPT Healthcare LtdGPTHEALTH | 47.9/100Mixed-negative evidence70% evidence | TURNING | 10.3/35 Revenue 16% · PAT -14% · OPM change -2 pp 83% evidence | 18.5/25 ROCE 19.9% · OPM 18% 95% evidence | 11.2/20 P/E 32.5× · PEG — 15% evidence | 7.9/20 RS sector -15.8% · RS bench 17.9% · 1Y 5.9%10 of 10 weeks ahead 70% evidence |
| Exact sum: 10.3 + 18.5 + 11.2 + 7.9 = 47.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Aster DM Quality Care LtdASTERDM | 39.4/100Mixed-negative evidence96% evidence | LEADER | 12.6/35 Revenue 12.2% · PAT -80% · OPM change 1 pp 88% evidence | 9.8/25 ROCE 11.4% · OPM 19% 100% evidence | 1.5/20 P/E 176× · PEG 3.07 100% evidence | 15.5/20 RS sector 10.8% · RS bench 19.6% · 1Y 41.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 9.8 + 1.5 + 15.5 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 19.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Krishna Institute of Medical Sciences LtdKIMS | 39.4/100Mixed-negative evidence78% evidence | LEADER | 10.4/35 Revenue 28.7% · PAT -41.5% · OPM change -6 pp 83% evidence | 9.2/25 ROCE 9.3% · OPM 19% 76% evidence | 5.5/20 P/E 136× · PEG — 50% evidence | 14.3/20 RS sector 3.7% · RS bench 12% · 1Y 5.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 10.4 + 9.2 + 5.5 + 14.3 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Narayana Hrudayalaya LtdNH | 39.3/100Mixed-negative evidence87% evidence | TURNING | 12.6/35 Revenue 59.6% · PAT 3.8% · OPM change -5 pp 100% evidence | 11.6/25 ROCE 15.5% · OPM 17% 100% evidence | 6.1/20 P/E 48.1× · PEG 3 65% evidence | 9.0/20 RS sector -4.3% · RS bench 9.2% · 1Y 1.9%5 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 11.6 + 6.1 + 9 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Healthcare Global Enterprises LtdHCG | 35.9/100Mixed-negative evidence65% evidence | TURNING | 13.1/35 Revenue 14.5% · PAT -53.4% · OPM change 1.1 pp 83% evidence | 7.4/25 ROCE 8.3% · OPM 19.2% 76% evidence | 8.5/20 P/E 349× · PEG — 15% evidence | 6.9/20 RS sector -8.1% · RS bench 3.4% · 1Y 18.5%8 of 10 weeks ahead 70% evidence |
| Exact sum: 13.1 + 7.4 + 8.5 + 6.9 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Shalby Ltdthis pageSHALBY | 30.7/100Adverse evidence69% evidence | ASLEEP | 15.6/35 Revenue 4.8% · PAT 100% · OPM change 2 pp 62% evidence | 2.5/25 ROCE 6.5% · OPM 10% 95% evidence | 9.1/20 P/E 46.6× · PEG — 50% evidence | 3.5/20 RS sector -28.4% · RS bench -14.9% · 1Y -22.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 15.6 + 2.5 + 9.1 + 3.5 = 30.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Jupiter Life Line Hospitals LtdJLHL | 29.8/100Adverse evidence100% evidence | BASING | 8.4/35 Revenue 14.7% · PAT -3.1% · OPM change -3 pp 100% evidence | 10.5/25 ROCE 14.8% · OPM 19% 100% evidence | 6.4/20 P/E 56.9× · PEG 3.44 100% evidence | 4.5/20 RS sector -74.8% · RS bench 17.9% · 1Y -77.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 8.4 + 10.5 + 6.4 + 4.5 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Shalby Ltd's share price today?
Shalby Ltd trades at ₹161, −21.6% over the past year. The company is valued at ₹1,742 Cr. The stock sits at 22% of its 52-week range of ₹131–₹266, −8.7% versus its 200-day average. On the tape, the price is in a downtrend, 32 weeks in. — as of 31 July 2026.
What were Shalby Ltd's latest quarterly results?
Shalby Ltd reported revenue of ₹287 Cr and net profit of ₹18.0 Cr for the Mar 26 quarter. Earnings per share were ₹1.70. The operating margin was 10.0%, 2.0 pp higher than a year earlier. — as of 31 July 2026.
What is Shalby Ltd's revenue?
Shalby Ltd reported revenue of ₹287 Cr in the Mar 26 quarter, +8.3% year on year. For the full FY26 fiscal year, revenue was ₹1,141 Cr (+5.0%). Over the last 10 years revenue compounded at 14.7% a year. — as of 31 July 2026.
What is Shalby Ltd's profit?
Shalby Ltd earned ₹18.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹35.0 Cr. The operating margin ran 10.0% in the latest quarter. — as of 31 July 2026.
What is Shalby Ltd's market cap?
Shalby Ltd's market capitalisation is ₹1,742 Cr at a share price of ₹161. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Shalby Ltd's P/E ratio?
Shalby Ltd trades at a P/E of 46.6×, at the 72nd percentile of its own 9-year range, against a long-run median of 37.1×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Shalby Ltd pay a dividend?
Not in its latest year — Shalby Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 6 of its last 13 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Shalby Ltd overvalued?
On its own history, Shalby Ltd looks expensive against its own history: its P/E of 46.6× sits at the 72nd percentile of its 9-year range (long-run median 37.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
How is Shalby Ltd performing?
Shalby Ltd is in a downtrend, 32 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Shalby Ltd in?
Turning around — profit growth swung from −100.0% at the trough to +250.0%, a 2-quarter improving streak (single-quarter readings), ROCE slipping at 6.0%. The read comes from the last 12 quarters of growth (revenue growth +8.3% latest, profit growth +250.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Shalby Ltd in an uptrend?
No — the price is in a downtrend (week 32 of stage 4), trading −8.7% versus its 200-day average and at 22% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Shalby Ltd beating the market?
Not lately — on a trailing-13-week view Shalby Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-07-10), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 8.6 years the stock moved −33% against the NIFTY 500's +151% — behind the index over the full window. — as of 31 July 2026.
Will Shalby Ltd's share price go up?
This page publishes no price forecast for Shalby Ltd. What it measures instead: the share price is ₹161, the price is in a downtrend 32 weeks in. Its P/E of 46.6× sits at the 72nd percentile of its own 9-year range. Direction is not something this site claims to know. — as of 31 July 2026.
Who owns Shalby Ltd?
Promoters hold 74.3% of Shalby Ltd, foreign institutions 4.5%, domestic institutions 0.3% and the public 20.3% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Shalby Ltd have too much debt?
It is moderate — Shalby Ltd's debt-to-equity is 0.59, and operating profit covers the interest bill 4×. FY26 borrowings were ₹595 Cr against equity of ₹1,006 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Shalby Ltd's capex?
Shalby Ltd spent ₹556 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹157 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Shalby Ltd's cash flow?
Shalby Ltd generated ₹0.0 Cr of operating cash flow in FY26 and ₹−157 Cr of free cash flow after ₹157 Cr of capital spending. Reported profit that year was ₹35.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Shalby Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 13% of Shalby Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹0.0 Cr against reported profit of ₹35.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.
Where is Shalby Ltd in its business cycle?
Shalby Ltd's FY26 operating margin was 13.0%, against a 13-year band of 12.0%–25.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 10.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Shalby Ltd story?
The sharpest disagreement: profits are rising, but only 13% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Shalby Ltd a stock worth studying right now?
This is not investment advice. The machine read: Shalby Ltd's earnings have outrun its stock. EPS grew +496.6% in a year against a −21.6% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.